ArticleMarine drugs2013
Cytotoxic, cytostatic and HIV-1 PR inhibitory activities of the soft coral Litophyton arboreum.
Article in Marine drugs, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 47 citations in OpenAlex.
- Review
- Botany, traditional uses, phytochemistry, pharmacology, toxicology and processing ofFrontiers in pharmacology · 2025Review
- New sesquiterpenes from the soft coral Litophyton arboreum.Journal of natural medicines · 2025Article
- New Meroterpenes from South China Sea Soft CoralMarine drugs · 2024Article
- GenusMarine drugs · 2023Review
- Sesquiterpenoids from Meliaceae Family and Their Biological Activities.Molecules (Basel, Switzerland) · 2023Review
- Enzyme Inhibitors from Gorgonians and Soft Corals.Marine drugs · 2023Review
- The Antioxidant and Antitumor Efficiency ofLife (Basel, Switzerland) · 2022Article
- Potential of Marine Terpenoids against SARS-CoV-2: AnBiomedicines · 2021Article
- Bioactive Steroids from the Red Sea Soft CoralMarine drugs · 2020Article
- Natural Products Repertoire of the Red Sea.Marine drugs · 2020Review
- Coral and Coral-Associated Microorganisms: A Prolific Source of Potential Bioactive Natural Products.Marine drugs · 2019Review
- Alcyonacea: A Potential Source for Production of Nitrogen-Containing Metabolites.Molecules (Basel, Switzerland) · 2019Review
- Review
- Molecular architecture and biomedical leads of terpenes from red sea marine invertebrates.Marine drugs · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bioassay-guided fractionation using different chromatographic and spectroscopic techniques in the analysis of the Red Sea soft coral Litophyton arboreum led to the isolation of nine compounds; sarcophytol M (1), alismol (2), 24-methylcholesta-5,24(28)-diene-3β-ol (3), 10-O-methyl alismoxide (4), alismoxide (5), (S)-chimyl alcohol (6), 7β-acetoxy-24-methylcholesta-5-24(28)-diene-3,19-diol (7), erythro-N-dodecanoyl-docosasphinga-(4E,8E)-dienine (8), and 24-methylcholesta-5,24 (28)-diene-3β,7β,19-triol (9). Some of the isolated compounds demonstrated potent cytotoxic- and/or cytostatic activity against HeLa and U937 cancer cell lines and inhibitory activity against HIV-1 protease (PR). Compound 7 was strongly cytotoxic against HeLa cells (CC₅₀ 4.3 ± 0.75 µM), with selectivity index of SI 8.1, which was confirmed by real time cell electronic sensing (RT-CES). Compounds 2, 7, and 8 showed strong inhibitory activity against HIV-1 PR at IC₅₀s of 7.20 ± 0.7, 4.85 ± 0.18, and 4.80 ± 0.92 µM respectively. In silico docking of most compounds presented comparable scores to that of acetyl pepstatin, a known HIV-1 PR inhibitor. Interestingly, compound 8 showed potent HIV-1 PR inhibitory activity in the absence of cytotoxicity against the cell lines used. In addition, compounds 2 and 5 demonstrated cytostatic action in HeLa cells, revealing potential use in virostatic cocktails. Taken together, data presented here suggest Litophyton arboreum to contain promising compounds for further investigation against the diseases mentioned.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.